[go: up one dir, main page]

WO2004030637A3 - Traitement de l'obesite et d'autres troubles associes a une consommation alimentaire excessive - Google Patents

Traitement de l'obesite et d'autres troubles associes a une consommation alimentaire excessive Download PDF

Info

Publication number
WO2004030637A3
WO2004030637A3 PCT/US2003/009717 US0309717W WO2004030637A3 WO 2004030637 A3 WO2004030637 A3 WO 2004030637A3 US 0309717 W US0309717 W US 0309717W WO 2004030637 A3 WO2004030637 A3 WO 2004030637A3
Authority
WO
WIPO (PCT)
Prior art keywords
obesity
food intake
disorders associated
treatment
excessive food
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/009717
Other languages
English (en)
Other versions
WO2004030637A2 (fr
Inventor
Margaret J Bradbury
Nicholas D P Cosford
Mark A Varney
Jeffery J Anderson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2002/031294 external-priority patent/WO2003029210A2/fr
Priority claimed from PCT/US2002/041720 external-priority patent/WO2003051315A2/fr
Priority claimed from PCT/US2002/040147 external-priority patent/WO2003051833A2/fr
Priority claimed from PCT/US2002/040237 external-priority patent/WO2003053922A2/fr
Priority claimed from PCT/US2002/040486 external-priority patent/WO2003059904A1/fr
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Priority to AU2003218462A priority Critical patent/AU2003218462A1/en
Publication of WO2004030637A2 publication Critical patent/WO2004030637A2/fr
Publication of WO2004030637A3 publication Critical patent/WO2004030637A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des modulateurs des récepteurs 5 métabotropiques du glutamate (mGluR5) utiles pour traiter des troubles associés à une consommation alimentaire excessive, y compris l'obésité et les troubles associés à l'obésité. Plus particulièrement, l'invention concerne les antagonistes des mGluR5 représentés par les formules IA-IF, lesquels sont utiles pour traiter de telles affections soit en tant qu'agents uniques, soit en combinaison avec d'autres composés utilisés pour le traitement de l'obésité.
PCT/US2003/009717 2002-10-01 2003-03-31 Traitement de l'obesite et d'autres troubles associes a une consommation alimentaire excessive Ceased WO2004030637A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003218462A AU2003218462A1 (en) 2002-10-01 2003-03-31 Treatment of obesity and other disorders associated with excessive food intake

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
PCT/US2002/031294 WO2003029210A2 (fr) 2001-10-04 2002-10-01 Composes de tetrazole substitues par heteroaryle, modulateurs du recepteur-5 metabotropique du glutamate
USPCT/US02/31294 2002-10-01
USPCT/US02/40147 2002-12-13
PCT/US2002/041720 WO2003051315A2 (fr) 2001-12-18 2002-12-13 Modulateurs triazole substitues par heteroaryle du recepteur metabotropique 5 du glutamate
PCT/US2002/040147 WO2003051833A2 (fr) 2001-12-18 2002-12-13 Modulateurs pyrazole a substitution heteroaryle du recepteur 5 metabotropique de glutamate
USPCT/US02/41720 2002-12-13
USPCT/US02/40237 2002-12-16
PCT/US2002/040237 WO2003053922A2 (fr) 2001-12-19 2002-12-16 Imidazoles substitues par heteroaryle modulateurs du recepteur metabotropique du glutamate de type 5
PCT/US2002/040486 WO2003059904A1 (fr) 2001-12-21 2002-12-17 Modulateurs pyrrole a substitution heteroaryle du recepteur 5 metabotropique du glutamate
USPCT/US02/40486 2002-12-17

Publications (2)

Publication Number Publication Date
WO2004030637A2 WO2004030637A2 (fr) 2004-04-15
WO2004030637A3 true WO2004030637A3 (fr) 2004-09-23

Family

ID=32074735

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/009717 Ceased WO2004030637A2 (fr) 2002-10-01 2003-03-31 Traitement de l'obesite et d'autres troubles associes a une consommation alimentaire excessive

Country Status (2)

Country Link
AU (1) AU2003218462A1 (fr)
WO (1) WO2004030637A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006071730A1 (fr) * 2004-12-27 2006-07-06 Astrazeneca Ab Composes de pyrazolone utilises comme agonistes du recepteur de glutamate metabotropique pour le traitement de troubles neurologiques et psychiatriques
EP2513087A1 (fr) * 2009-12-18 2012-10-24 NeuroSearch A/S Dérivés du tétrazole en tant que modulateurs des récepteurs nicotiniques de l'acétylcholine
ME03564B (fr) 2013-03-13 2020-07-20 Forma Therapeutics Inc Nouveaux composés et compositions pour l'inhibition de fasn
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
CN112020500A (zh) 2017-12-22 2020-12-01 拉文纳制药公司 作为磷脂酰肌醇磷酸激酶抑制剂的氨基吡啶衍生物
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
CN113382633A (zh) 2018-10-29 2021-09-10 福马治疗股份有限公司 (4-(2-氟-4-(1-甲基-1H-苯并[d]咪唑-5-基)苯甲酰基)哌嗪-1-基)(1-羟基环丙基)甲酮的固体形式
TW202112767A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
MX2023009059A (es) 2021-02-02 2023-09-15 Liminal Biosciences Ltd Antagonistas de gpr84 y usos de estos.
PL247051B1 (pl) * 2022-11-29 2025-05-05 Univ Medyczny W Lublinie N-podstawione pochodne 1-(1-fenylo-3-arylo)-1H-pirazol-4-ylo) metanaminy, sposób ich wytwarzania i ich zastosowanie
WO2025212908A1 (fr) * 2024-04-04 2025-10-09 Nimbus Clio, Inc. Modulateurs de cbl-b et leurs utilisations

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS [online] 3 January 2001 (2001-01-03), REIMANN E. ET AL: "Intramolecular alkylation of aromatic compounds. Part XXXIV. Synthesis of (pyridinylmethyl)indoles as potential precursors of ergolines", XP002981277, Database accession no. (ACC178709) *
KOST ET AL: "Reactions of Hydrazine Derivatives", OBSHCH. KHIM., vol. 33, no. 11, 1963, pages 3603 - 3613, XP002981296 *
PHAMAZIE, vol. 55, no. 12, 2000, pages 907 - 912, XP002903667 *

Also Published As

Publication number Publication date
AU2003218462A8 (en) 2004-04-23
AU2003218462A1 (en) 2004-04-23
WO2004030637A2 (fr) 2004-04-15

Similar Documents

Publication Publication Date Title
MY120601A (en) C-21 modified epothilones
AU2003299791A1 (en) Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
AU2003207717B9 (en) 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
WO2004030637A3 (fr) Traitement de l'obesite et d'autres troubles associes a une consommation alimentaire excessive
HRP20041180A2 (en) 11-beta-hidroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
WO2008011453A3 (fr) HÉTÉROCYCLES AROMATIQUES D'AZOLE SUBSTITUÉS, UTILISÉS EN TANT QU'INHIBITEURS DE LLβ-HSD-1
AU2003281978A1 (en) 2,5-diketopiperazines for the treatment of obesity
AU2003272285A1 (en) Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands
WO2005032488A3 (fr) Sulfonylurees 2,4-dioxo-3-quinazolinylaryl
WO2006015371A3 (fr) Antagonistes anti-cmet humanises
WO2008019357A3 (fr) Composés d'indole
WO2006105345A3 (fr) Compositions et procedes pour le controle, la prevention et le traitement de l'obesite et des troubles de l'alimentation
AU2003289888A1 (en) Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders
IL176648A0 (en) (3-oxo-3,4-dihydro-quinoxalin-2-yl-amino)-benzamide derivatives and related compound as glycogen phosphorylase inhibitors for the treatment of diabetes and obesity
WO2004100875A3 (fr) Benzimidazoles, compositions contenant lesdits composes et methodes d'utilisation
WO2007041365A3 (fr) Composes organiques
WO2003101397A3 (fr) Vaccins tetravalents contre la dengue
WO2006014618A3 (fr) Pyrazoles substitues, compositions contenant de tels composes et leurs methodes d'utilisation
WO2005039504A3 (fr) Composes et methodes permettant de traiter les maladies et etats pathologiques lies au recepteur 2 de type toll
WO2005115439A3 (fr) Derives de cerberus/coco et leurs applications
WO2006017055A3 (fr) Derives de pyrazole amide, compositions contenant de tels composes et procedes d'utilisation
WO2005016883A3 (fr) Derives d'acrylamide servant d'antagonistes de l'integrine vla-1, et leurs utilisations
WO2002070469A3 (fr) Inhibiteurs selectifs de pde3b et leurs utilisations therapeutiques
AU2003210917A1 (en) Synergistic blend of antifungal bacillus strains
WO2005108428A3 (fr) Variants d'epissage de cd40 et leurs utilisations

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP